Wired News – Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

Stock Monitor: Bovie MedicalPost Earnings Reporting

LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company’s latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company’s Self-Cleaning Shunt (SCS). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=BVX

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Microbot Medical most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=MBOT

About the Self-Cleaning Shunt

The Microbot SCS is a robotic system, specifically designed as the ventricular catheter portion of a Cerebrospinal Fluid (CSF) shunt system. Microbot’s ventricular catheter is able to connect to existing valves and maintain CSF flow through the ventricular catheter. This SCS device has the potential to replace all ventricular catheters, and also significantly reduce shunts occlusions. At present, there is a 40% rate of occlusions within the first year of implementation.

Encouraging Results from the In-Vitro Study

Dr. Carolyn Harris, Assistant Professor of Chemical Engineering and Materials Science at Wayne State University conducted the study in an in-vitro 3D cell culture system, in order to replicate the ventricular environment. The study, which was conducted at the Wayne State University, validates SCS’s potential as a feasible technology for preventing occlusion in shunts used to treat hydrocephalus.

Dr. Harris shared that the initial results from the study demonstrate that cells attach, grow, and spread across the shunt drainage holes of the Microbot SCS. This study shows that Microbot SCS has the potential to remove the early spreading of cells across the shunt holes, which is a first step towards the main target of the study, i.e. occlusion prevention. However, further research is required to confirm this.

Harel Gadot, Chief Executive Officer, President, and Chairman at Microbot Medical, stated that these encouraging results affirm the Company’s confidence in the SCS’ technology, which is a novel solution to avert occlusion in hydrocephalus shunts, and also a potential platform for future occlusion prevention devices for other medical applications. The Company has been executing the next development phase of its SCS and has recently upgraded its facility to support these activities.

According to Gadot, with these improvements, Microbot expects to deliver the first occlusion prevention device for the numerous patients suffering from hydrocephalus while eliminating redundant procedures and reducing the cost of healthcare.

A US Patent for SCS

On May 09, 2018, Microbot announced that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Patent Application No. 15/187,003, for the Company’s SCS device. This application is a continuation of Patent No. 9,393,389, which was issued on July 19, 2016.

Way Ahead for SCS

Microbot intends to initiate larger-scale studies to support the SCS and prepare it for regulatory submissions in the USA, Europe, and other regions of the world.

Stock Performance Snapshot

May 22, 2018 – At Tuesday’s closing bell, Microbot Medical’s stock dropped 4.62%, ending the trading session at $0.91.

Volume traded for the day: 2.19 million shares, which was above the 3-month average volume of 309.11 thousand shares.

Stock performance in the last month – up 14.65%; and previous three-month period – up 13.97%

After yesterday’s close, Microbot Medical’s market cap was at $38.00 million.

The stock is part of the Healthcare sector, categorized under the Medical Instruments & Supplies industry.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 500568